Canine Diabetes: Why Fructosamine Beats Spot Glucose for Monitoring

A single blood glucose measurement tells you what the dog ate two hours ago, how stressed it was during the blood draw, and whether it received its insulin at the right time this morning. It does not tell you how the dog's glucose has been managed over the past three weeks. For adjusting insulin doses in diabetic dogs, that time-averaged picture is what matters — and a spot glucose provides almost none of it.

Fructosamine, by contrast, measures glycated serum proteins and reflects average blood glucose over the preceding 2-3 weeks. For the management question clinicians need to answer at a recheck visit — is this dog's insulin protocol working — fructosamine is the appropriate test.

Why Dogs Are Different From Cats

Feline diabetes involves different pathophysiology, different insulin options, and crucially, the possibility of remission. Cats that achieve tight glycemic control in the first 4-6 months of diagnosis may enter remission and no longer require insulin. The monitoring strategy for cats therefore includes more frequent glucose curves and more aggressive pursuit of normoglycemia in the early treatment period.

Canine diabetes mellitus, with rare exceptions, is a permanent insulin-dependent condition. Remission does not occur in intact male dogs or most spayed females with diabetes. The management goal shifts from remission-seeking to stable glycemic control with quality-of-life preservation. That goal is better served by periodic fructosamine monitoring than by frequent glucose curves or daily home glucose checks in uncomplicated cases.

What Fructosamine Values Mean

Reference ranges vary slightly by laboratory, but as a general guide for dogs:

• <340 µmol/L — Well-controlled or possibly hypoglycemic
• 340-450 µmol/L — Acceptable control
• 450-500 µmol/L — Suboptimal control; consider dose adjustment
• >500 µmol/L — Poor control; reassess protocol, compliance, and concurrent conditions

The lower end of this range — values below 340 µmol/L — warrants as much attention as the upper end. A dog presenting with fructosamine of 280 µmol/L may be experiencing recurrent hypoglycemia that the owner has not noticed. Hypoglycemia in dogs can manifest as episodes of stumbling, exercise intolerance, or behavioral change that owners attribute to aging rather than to glucose fluctuation.

When Fructosamine Is Unreliable

Fructosamine reflects glycation of serum proteins, primarily albumin. Any condition that reduces serum protein concentration or accelerates protein turnover will shorten the half-life of the glycated proteins and produce a falsely low fructosamine value despite poor glycemic control.

The main confounds:

• Hypoalbuminemia: In dogs with protein-losing nephropathy, protein-losing enteropathy, or severe hepatic insufficiency, fructosamine will underestimate the degree of hyperglycemia. For diabetic dogs with concurrent PLE or PLN, use glucose curves rather than fructosamine as the primary monitoring tool.
• Hyperthyroidism (less common in dogs): Accelerated metabolic rate increases protein turnover, shortening the apparent fructosamine window.
• Recent blood transfusion: Donor proteins with different glycation states dilute the patient's own fructosamine signal. Wait 3-4 weeks after transfusion before interpreting fructosamine.

Home Glucose Monitoring: When It Adds Value

For the majority of stable, well-controlled diabetic dogs, home glucose monitoring does not meaningfully improve outcomes compared to periodic clinic fructosamine checks. It does, however, add value in specific circumstances:

• Dogs with recent insulin dose changes (home monitoring during the 1-2 week adjustment period)
• Dogs with history of hypoglycemic episodes
• Dogs with concurrent infections, Cushing's, or other insulin-resistance-causing conditions where glucose needs close tracking during treatment
• Owner preference in highly engaged clients who want more active involvement in management

Continuous glucose monitoring (CGM) devices — the same category as FreeStyle Libre in human diabetes — have been adapted for use in dogs with good results at several veterinary internal medicine programs. Adherence of the sensor to the dog's skin requires some owner training, but the data quality over 14-day periods is substantially better than intermittent spot checks. CGM is appropriate for dogs with unstable diabetes or Somogyi rebound where understanding the 24-hour glucose curve is needed.

Identifying Insulin Resistance

A diabetic dog with persistently elevated fructosamine despite escalating insulin doses has insulin resistance rather than inadequate dosing. The most common causes in order of frequency:

1. Concurrent Cushing's disease (hyperadrenocorticism)
2. Concurrent infection — especially urinary tract infection, which is common in diabetic dogs and frequently subclinical
3. Progesterone — diestrus in intact females dramatically increases insulin resistance; intact female dogs with diabetes should be spayed during the first regulated period if possible
4. Pancreatitis (active or recurrent)
5. Anti-insulin antibodies — rare but documented with some insulin preparations

A diabetic dog requiring more than 1.5 U/kg per injection without achieving fructosamine below 500 µmol/L should have a urinalysis culture, cortisol testing, and abdominal imaging before any further dose escalation. Increasing insulin in an insulin-resistant dog without addressing the cause adds risk without benefit.